◀ Back to PRKAR2A
GRAP2 — PRKAR2A
Text-mined interactions from Literome
Zhang et al., J Neurochem 1999
(Glioma...) :
Inhibition of
protein kinase A (PKA) strongly
diminished p38 activation mediated by DOR or ORL1 but had no significant effect on ERK activation, and protein kinase C ( PKC ) inhibitors potentiated stimulation of p38 while inhibiting activation of ERKs
Cao et al., J Biol Chem 2001
:
The
involvement of
PKA in beta ( 3 ) AR-dependent
p38 MAPK activation was confirmed by the ability of the PKA inhibitors H89 ( 20 microm ) and ( R ( p ) ) -cAMP-S ( 1 mm ) to block phosphorylation of p38 MAPK
Rius et al., Arterioscler Thromb Vasc Biol 2004
(Calcium Signaling...) :
The upregulation of NOR-1 mRNA levels by LDL involves pertusis-sensitive G protein coupled receptors, Ca2+ mobilization,
protein kinases A (PKA) and C ( PKC )
activation , and mitogen activated protein kinase pathways ( MAPK ) ( p44/p42 and
p38 )
Pasapera et al., J Steroid Biochem Mol Biol 2005
:
Transactivation of estrogen-sensitive genes by FSH or PKA activators were blocked ( approximately 90 % ) by H89 (
PKA inhibitor ) and LY294002 but not by Wortmannin ( PI3-K inhibitors ), 4-OH-tamoxifen, ICI182,780 or SB203580 (
p38 MAPK inhibitor ) ; PD98059 ( ERK1/2 inhibitor ) partially ( approximately 30 % ) blocked the FSH mediated effect
Launay et al., Exp Cell Res 2006
:
Upstream of p38, we found that RhoK, PKC and
PKA are selectively
involved in the activation of
p38 and phosphorylation of alphaB-crystallin, depending on the cytoskeletal network disorganized
Saha et al., Pigment Cell Res 2006
:
Moreover, we also show that activation of
p38 mediated by lipids is
potentiated by inhibition of the PI3kinase pathway but not by inhibition of
protein kinase A (PKA)
Chen et al., Cancer Res 2007
(Breast Neoplasms) :
Specific activation of
protein kinase A (PKA) or EPAC with cAMP analogues
stimulated p38 and JNK1 ; however, only PKA activating cAMP analogues induced aromatase expression
Somvanshi et al., Int J Cardiol 2013
(Cardiomegaly) :
SST
enhances ß2AR agonist formoterol mediated effects on
PKA , CREB and ERK1/2 phosphorylations whereas it inhibits isoproterenol mediated ERK1/2 and
p38 signaling in concentration dependent manner